Chimeric Immunoglobulin Standard for Anti-HLA Antibody Quantification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting and quantifying anti-HLA antibodies in transplant patients are inefficient, lacking sensitivity and standardization, leading to unreliable results and variability in fluorescence intensity measurements, which complicates the identification of specific antibodies and the assessment of hyperacute humoral rejection risks.
Innovation Solution
A monoclonal chimeric immunoglobulin with a specific structure, comprising heavy and light chains, is developed to serve as a standardization and calibration reagent for accurate detection and quantification of anti-HLA antibodies, using a stable aqueous solution with a known concentration, suitable for various techniques such as immunofluorimetry and flow cytometry.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods (complement-dependent microlymphocytotoxicity, ELISA, flow immunofluorimetry) are used for detecting anti-HLA antibodies, then detection capability is achieved, but measurement precision and reliability are poor due to lack of standardization and high variability in fluorescence intensity
Solution Approach 1:
The patent introduces a monoclonal chimeric immunoglobulin with defined structural parameters (heavy chain variable region from anti-HLA class I or II antibody, heavy chain constant region from human IgG/IgA/IgM, light chain variable region from anti-HLA antibody, light chain constant region from kappa or lambda) and controlled concentration (10^-10 to 10^-4 g/ml) to serve as a standardized reference, enabling precise and reliable quantification of anti-HLA antibodies by providing a consistent measurement baseline across different assays
Solution Approach 2:
The monoclonal chimeric immunoglobulin acts as an intermediary standardization reagent between the detection system (beads, flow cytometry, ELISA) and the anti-HLA antibodies being measured. By spiking patient samples with known concentrations of this chimeric immunoglobulin, the patent creates a calibrated reference system that mediates the measurement process and enables accurate quantification and comparison across different laboratories and methods
2Reliability
If polyclonal antibodies from patient sera are used as positive control, then detection of anti-HLA antibodies is possible, but manufacturing precision and standardization are poor due to batch-to-batch variability and unknown concentrations
Solution Approach 1:
The patent creates an artificial copy or model of anti-HLA antibodies with precisely controlled properties. Instead of using natural polyclonal antibodies from patient sera with variable compositions, the invention synthesizes a monoclonal chimeric immunoglobulin with defined sequence information (SEQ ID NOs 1-8), known concentration, and reproducible batch-to-batch characteristics, serving as a standardized positive control that can be manufactured with high precision
Solution Approach 2:
The monoclonal chimeric immunoglobulin is a composite molecular structure combining elements from different antibody sources: variable regions from anti-HLA class I or II monoclonal antibodies and constant regions from human immunoglobulins. This composite design allows the molecule to retain anti-HLA binding specificity while providing human-compatible constant regions and standardized, reproducible properties for use as a reference material
3Measurement precision
If standardization reagents are introduced to improve measurement precision, then quantification accuracy improves, but device complexity and assay procedure complexity increase
Solution Approach 1:
The monoclonal chimeric immunoglobulin is designed as a universal standardization reagent that can be used across multiple different assay platforms and techniques including flow cytometry, ELISA, and other immunoenzymatic assays. The single reagent serves multiple functions: as a positive control, as a calibration standard for quantification, and as a reference for batch-to-batch comparison, thereby simplifying the overall standardization process despite the added reagent
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The monoclonal chimeric immunoglobulin enables reliable and standardized detection of anti-HLA antibodies, allowing for early identification of humoral rejection and providing a calibrated method for quantification, thereby improving transplant monitoring and reducing the risk of organ rejection.
Implementation Method 1
anti-HLA monoclonal chimeric immunoglobulin which is suitable for use especially as a standardisation reagent for the screening and quantification of anti-HLA antibodies in a liquid medium
Data Source
AI summary
A monoclonal chimeric immunoglobulin wherein the heavy chains and the light chains are human by nature in their constant parts, in particular, the heavy chain constant parts are chosen from the group formed of the heavy chain constant parts of an IgA, of an IgG or of an IgM and the light chain constant parts are chosen from the group formed of the kappa chains and the lambda chains, and the light chain and the heavy chain variable parts are chosen from the group formed of monoclonal antibodies specific to monomorphic epitopes of HLA class I antigens and monoclonal antibodies specific to monomorphic epitopes of HLA class II antigens. A process for standardization of the screening and for quantification of anti-HLA antibodies in a liquid medium is also described.